Neurocrine Biosciences Reports 39.4% Revenue Growth to $959M in Q2 2026

Neurocrine Biosciences, Inc. reported significant financial growth in its latest quarterly filing, with total revenues reaching $959.0 million for the three months ended June 30, 2026, a 39.4% increase from $687.5 million in the same period last year. For the first half of 2026, revenues totaled $1.77 billion, up 40.6% from $1.26 billion in the first half of 2025. The increase was primarily driven by strong sales of its products, particularly the recently launched CRENESSITY® and the inclusion of VYKAT® XR sales following the acquisition of Soleno Therapeutics, Inc. The company reported a net income of $144.4 million for the second quarter, compared to $107.5 million in the prior year, resulting in diluted earnings per share of $1.39, up from $1.06.

The company experienced notable changes in its financial position compared to the previous fiscal period. Total current assets decreased to $1.64 billion as of June 30, 2026, from $2.52 billion at the end of 2025, largely due to a reduction in cash and cash equivalents, which fell to $332.4 million from $713.0 million. This decline was attributed to the cash outflow related to the acquisition of Soleno, which was completed in May 2026 for approximately $2.83 billion. The acquisition added VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio, enhancing its position in the rare disease market.

Operationally, Neurocrine reported increased engagement metrics, with net product sales for INGREZZA® rising to $716.5 million in the second quarter, up from $624.4 million a year earlier. CRENESSITY sales reached $183.5 million, a significant increase from $53.2 million in the same quarter of 2025. The company also reported that VYKAT XR generated $54.3 million in sales since its launch. The total number of shares outstanding increased to 101.6 million as of June 30, 2026, reflecting ongoing stock-based compensation and equity awards.

Looking ahead, Neurocrine's management expressed optimism about the company's growth trajectory, supported by its expanded product portfolio and ongoing clinical development programs. The company has initiated several clinical studies, including a Phase 2 study for NBI-1117570 in schizophrenia and a Phase 1 study for NBIP-2118, a potential treatment for obesity. Additionally, Neurocrine has a robust pipeline of products in various stages of development, which it believes will drive future revenue growth. The company maintains a strong liquidity position with $1.0 billion available under its new credit facility, which it plans to utilize for general corporate purposes and to support its ongoing research and development efforts.